VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+59.81%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.46B
AUM Growth
+$1.46B
(+53%)
Cap. Flow
+$69.2M
Cap. Flow
% of AUM
4.75%
Top 10 Holdings %
Top 10 Hldgs %
68.34%
Holding
42
New
5
Increased
14
Reduced
8
Closed
6
Top Buys
| 1 |
Pharvaris
PHVS
|
$51.4M |
| 2 |
Spyre Therapeutics
SYRE
|
$44.7M |
| 3 |
Ocular Therapeutix
OCUL
|
$34.7M |
| 4 |
Arvinas
ARVN
|
$25.8M |
| 5 |
Astria Therapeutics
ATXS
|
$24.8M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$27.3M |
| 2 |
Travere Therapeutics
TVTX
|
$23.5M |
| 3 |
Savara
SVRA
|
$17.3M |
| 4 |
GH Research
GHRS
|
$8.27M |
| 5 |
Taysha Gene Therapies
TSHA
|
$7.14M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lyra Therapeutics
LYRA
$11.8M
| $13.5M | 0.93% |
2,575,593
+1,651,423
| +179% | +$8.65M |
|
|
ABVX
27
Abivax
ABVX
$6.32B
| $10.7M | 0.73% |
+998,570
| New | +$10.7M |
|
28
Dianthus Therapeutics
DNTH
$781M
| $9.65M | 0.66% |
927,706
| – | – |
|
29
Praxis Precision Medicines
PRAX
$980M
| $7.88M | 0.54% |
353,626
-4,950,784
| -93% | -$22 |
|
|
30
GH Research
GHRS
$870M
| $7.65M | 0.52% |
1,318,327
-1,425,798
| -52% | -$8.27M |
|
|
SLRN
31
DELISTED
ACELYRIN
SLRN
| $6.99M | 0.48% |
937,113
+72,781
| +8% | +$543K |
|
32
EyePoint Pharmaceuticals
EYPT
$827M
| $5.78M | 0.4% |
+250,000
| New | +$5.78M |
|
33
Trevi Therapeutics
TRVI
$871M
| $4.59M | 0.31% |
3,422,397
| – | – |
|
34
Adverum Biotechnologies
ADVM
$68.2M
| $3.88M | 0.27% |
5,147,547
-1,425,753
| -22% | -$1.07M |
|
35
Milestone Pharmaceuticals
MIST
$151M
| $1.54M | 0.11% |
925,048
-1,283,764
| -58% | -$2.14M |
|
36
Olema Pharmaceuticals
OLMA
$432M
| $1.08M | 0.07% |
77,042
| – | – |
|
37
Pliant Therapeutics
PLRX
$105M
| – | – |
-288,949
| Closed | -$5.01M |
|
38
Rallybio
RLYB
$24.1M
| – | – |
-268,532
| Closed | -$905K |
|
39
Aclaris Therapeutics
ACRS
$223M
| – | – |
-1,040,754
| Closed | -$7.13M |
|
|
AFMD
40
DELISTED
Affimed
AFMD
| – | – |
-1,428,571
| Closed | -$683K |
|
41
Sagimet Biosciences
SGMT
$239M
| – | – |
-515,000
| Closed | -$4.53M |
|
|
42
Travere Therapeutics
TVTX
$1.75B
| – | – |
-2,623,677
| Closed | -$23.5M |
|